| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Dihydroorotate dehydrogenase (quinone), mitochondrial, DHOdehase, Dihydroorotate oxidase, DHODH |
| Entrez GeneID | 1723 |
| WB Predicted band size | 42.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This DHODH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-194 amino acids from the Central region of human DHODH. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DHODH(Center)抗体的参考文献示例(注：文献为模拟示例，实际引用需查询具体数据库)：
---
1. **文献名称**: "Targeting DHODH in Acute Myeloid Leukemia: A Therapeutic Strategy"
**作者**: Smith J, et al.
**摘要**: 本研究利用针对DHODH蛋白中心结构域(氨基酸200-400)的兔源单克隆抗体(克隆号#ABC123)，通过免疫印迹和免疫组化分析急性髓系白血病(AML)细胞系中的DHODH表达。结果显示，DHODH高表达与白血病细胞增殖相关，抑制其活性可诱导细胞分化，提示其作为治疗靶点的潜力。
---
2. **文献名称**: "DHODH Inhibition Modulates Autoimmune Response in Rheumatoid Arthritis"
**作者**: Lee S, et al.
**摘要**: 通过使用抗DHODH中心区域的抗体(货号#CST456)，研究团队在类风湿性关节炎患者滑膜组织中检测DHODH的表达水平。实验表明，DHODH抑制剂通过阻断嘧啶合成通路减少炎性细胞因子释放，验证了抗体在组织定位中的特异性应用。
---
3. **文献名称**: "Mitochondrial Localization of DHODH in Neurodegenerative Diseases"
**作者**: Zhang Y, et al.
**摘要**: 本文采用靶向DHODH中心表位的抗体(品牌Abcam，货号#ab78901)，结合免疫荧光技术验证DHODH在线粒体中的定位。研究发现，阿尔茨海默病模型中DHODH表达上调，抑制其活性可减轻线粒体氧化应激，为神经保护机制提供新见解。
---
4. **文献名称**: "High-Throughput Screening of DHODH Inhibitors Using Antibody-Based Assays"
**作者**: Patel R, et al.
**摘要**: 开发了一种基于抗DHODH中心区域抗体的ELISA检测方法(抗体来源：Santa Cruz，货号#sc-12345)，用于高通量筛选小分子抑制剂。研究验证了该抗体的灵敏度和特异性，并成功筛选出新型DHODH抑制剂，可用于癌症和自身免疫疾病的药物开发。
---
**注意事项**：
- 实际引用时需通过PubMed、Google Scholar等平台检索真实文献(关键词：DHODH antibody, DHODH inhibitor, 研究领域+DHODH)。
- 抗体选择需结合实验需求(如物种来源、应用场景：WB/IHC/IF)，并参考厂商数据(如CST、Abcam官网的技术参数)。
The DHODH (dihydroorotate dehydrogenase) antibody targets the enzyme dihydroorotate dehydrogenase, a mitochondrial protein critical in the *de novo* pyrimidine biosynthesis pathway. DHODH catalyzes the fourth step in this pathway, converting dihydroorotate to orotate, which is essential for synthesizing nucleotides required for DNA/RNA production. As rapidly proliferating cells (e.g., cancer cells, activated immune cells) rely heavily on *de novo* pyrimidine synthesis, DHODH is a key metabolic regulator and a potential therapeutic target in oncology and autoimmune diseases.
The DHODH(Center) antibody is designed to recognize a central epitope of the DHODH protein, enabling specific detection in applications like Western blotting, immunohistochemistry, or immunofluorescence. Its development stems from the need to study DHODH expression and localization in various tissues or disease models, particularly in cancers (e.g., leukemia, melanoma) and inflammatory conditions. Research using this antibody has contributed to understanding DHODH’s role in cellular proliferation, mitochondrial function, and its interplay with immune responses. Additionally, DHODH inhibitors, such as teriflunomide (used in multiple sclerosis) or leflunomide (for rheumatoid arthritis), highlight the enzyme’s clinical relevance. The DHODH(Center) antibody thus serves as a vital tool for elucidating mechanisms of disease and evaluating therapeutic strategies targeting nucleotide metabolism.
×
